Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells

Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells

Drug resistance to existing anticancer agents is a growing clinical concern, with many first line treatments showing poor efficacy in treatment plans of some cancers. Resistance to platinum agents, such as cisplatin, is particularly prevalent in the treatment of ovarian cancer, one of the most commo...

Full description

Bibliographic Details
Main Authors: Jerneja Kladnik, James P. C. Coverdale, Jakob Kljun, Hilke Burmeister, Petra Lippman, Francesca G. Ellis, Alan M. Jones, Ingo Ott, Isolda Romero-Canelón, Iztok Turel
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
ruthenium
pyrithione
resistance to chemotherapy
cancer
ovarian
thioredoxin
Online Access:https://www.mdpi.com/2072-6694/13/10/2493

Similar Items

Similar Items